Pfizer/Washington U. Tie-Up Involves Reprofiling Of Existing Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Under five-year collaboration, university researchers will have access to more than 500 Pfizer compounds and their clinical and preclinical data.
You may also be interested in...
NIH Royalties For Pfizer, AstraZeneca, Lilly Drugs Remain Open Question In Repurposing Initiative
With collaborative research agreement templates that include many of the details for a licensing agreement, royalties will be the major issue to be resolved if researchers develop new IP for one of the firm’s abandoned compounds.
NIH Center Would Seek To Boost “Repurposing” Of Shelved Drug Candidates
A proposed new center at the National Institutes of Health dedicated to speeding “translation” of biomedical research into therapies may focus initially on exploring new uses for drug candidates shelved by pharmaceutical firms, according to NIH Director Francis Collins.
NIH Center Would Seek To Boost “Repurposing” Of Shelved Drug Candidates
A proposed new center at the National Institutes of Health dedicated to speeding “translation” of biomedical research into therapies may focus initially on exploring new uses for drug candidates shelved by pharmaceutical firms, according to NIH Director Francis Collins.